(EN)
Subject matter of the present invention is a method for (a) diagnosing or
predicting the risk of
life-threatening deterioration or an adverse event or (b) prognosing the
severity or (c) predicting
or monitoring the success of a therapy or intervention in a patient infected
with a Corona virus,
the method comprising:
= determining the level of pro-Adrenomedullin (SEQ ID No. 31) or fragment
thereof in a sample of bodily fluid of said patient,
= comparing said level of pro-Adrenomedullin or fragment thereof to a pre-
determined threshold or a previous level of pro-Adrenomedullin or fragment
thereof, and
= correlating said level of pro-Adrenomedullin or fragment thereof with the
risk
of life-threatening deterioration or an adverse event, or
= correlating said level of pro-Adrenomedullin or fragment thereof with the
severity, or
= correlating said level of pro-Adrenomedullin or fragment thereof with the
success of a therapy or intervention,
wherein said pro-Adrenomedullin or fragment thereof is selected from the group
consisting of
PAMP (SEQ ID No. 32), MR-proADM (SEQ ID No. 33), ADM-NH2 (SEQ ID No. 20), ADM-
Gly (SEQ ID No. 21) and CT-proADM (SEQ ID No. 34).
Subject matter of the present invention is an Anti-adrenomedullin (ADM)
antibody or anti-
ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy or
intervention in a
patient in a patient infected with a Corona virus.
